What Is VIP? Receptors, Selectivity and Stability

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

VIP is better characterised than most peptides in a research catalogue, and the characterisation points at a specific experimental difficulty: there are two receptors, they overlap, and a second endogenous ligand engages both of them. Any experiment attributing an effect to VIP signalling has to deal with that, and the literature on how to do so is unusually good.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

The molecule

Property	Value
Length	28 residues
Family	Secretin–glucagon superfamily
Architecture	Linear; helical when receptor-bound
Disulfide bridges	None
Receptors	VPAC1, VPAC2 (class B GPCRs)
Shares receptors with	PACAP
Stabilising modifications	None in the native sequence

Twenty-eight residues with no disulfide and no terminal protection is an unprotected molecule. Class B GPCR ligands of this kind typically bind as an extended helix, with the N-terminal region reaching into the receptor core and the C-terminal region held by the extracellular domain. That two-part binding mode is what the selectivity literature is really about.

The pharmacophore work, and why it still matters

Two companion papers by Igarashi and colleagues in the Journal of Pharmacology and Experimental Therapeutics in 2002 mapped the structural requirements for each receptor: one for VPAC1 across human, rat and guinea pig, and one for VPAC2 in human and rat with an explicit comparison against the VPAC1 pharmacophore.

Two features of that work are worth drawing out:

They were done across species. The VPAC1 paper covers three species, which means the pharmacophore is not a single-species artefact — and it also means species differences are documented rather than assumed away. For anyone working in a rodent model and reasoning from human data, this is the relevant check.
They were designed for comparison. The second paper explicitly contrasts the two receptors’ requirements. That is how a selectivity question gets answered properly: by mapping both, not by testing one.

The 2005 follow-up developed simplified VIP analogues with receptor selectivity and stability. The pairing of those two goals in one programme is informative: the group pursuing selectivity found stability to be a problem worth solving at the same time, which tells you something about the parent peptide.

What the structural work added

The 2022 paper by Piper and colleagues in Nature Communications addressed VPAC receptor family peptide binding and selectivity structurally. This is the reference to read if the question is why selectivity is hard rather than what the selective ligands are.

The short version is that the two receptors recognise overlapping features of the same ligand, so a modification that weakens binding to one often weakens binding to the other. Selectivity is achievable but it is won against the grain of the system, not by finding an obvious distinguishing contact.

The PACAP problem

This is the design point most often missed. PACAP is a related peptide that engages both VPAC receptors, in addition to having its own PAC1 receptor. The consequences for experiments:

Situation	Issue
Endogenous PACAP present in the system	Baseline VPAC occupancy is not zero
Antibody or assay raised against one family member	Cross-reactivity is plausible and should be checked
Effect attributed to VIP	Needs VPAC1/VPAC2 discrimination, not just VIP addition
Comparison of VIP and PACAP	Confounded by PAC1, which only PACAP engages

None of this makes VIP a difficult reagent to use. It makes it a reagent whose results need careful attribution, which is a different thing — and the pharmacophore and structural literature above is exactly what makes the careful version possible.

Handling

A 28-residue unprotected linear peptide is a moderately demanding reagent.

Store sealed lyophilized material at −20 °C, dry and dark. Let the vial warm before opening so moisture does not condense into the powder.
Reconstitute gently, down the vial wall, with swirling. Peptides of this length can aggregate under shear.
Aliquot on first reconstitution. Proteolysis is the dominant route in any protease-containing medium, and repeated warming of one tube is the common avoidable loss. See storing reconstituted peptides.
Expect surface loss in dilute working solutions. Carrier protein is used where the assay tolerates it.
Compute molarity from net peptide content, not vial weight; the counterion and residual water are real mass. Our reconstitution calculator takes those figures from the certificate.

One stability point specific to this peptide: because the parent is unmodified and the published analogue programme targeted stability explicitly, a VIP experiment in serum-containing medium is operating on a short timescale. Where the readout is slow, the exposure may not last as long as the incubation.

Our VIP research material is supplied for laboratory research use. Certificates are available for listed products — contact us for the latest report. For a 28-mer, the chromatogram is worth examining: deletion impurities from synthesis are a real possibility at this length and they are the ones most likely to co-elute. See how to read a certificate of analysis.

Scope note

This material is supplied for laboratory research use only. It is not a medicine, not a supplement, and not for human or veterinary use. The content above concerns peptide structure, receptor pharmacology and handling chemistry.

Open questions

How complete is VPAC1/VPAC2 selectivity in the best available analogues?
How large are the species differences documented in the pharmacophore work, in practice?
What is VIP’s measured stability in common culture media?

Frequently asked questions

What is VIP?

Vasoactive intestinal peptide: a 28-residue peptide of the secretin-glucagon family, originally isolated from intestinal tissue. It signals through two class B G protein-coupled receptors, VPAC1 and VPAC2, and shares those receptors with the related peptide PACAP.

What receptors does VIP act on?

VPAC1 and VPAC2. Both are class B GPCRs and both are also engaged by PACAP, which means a readout attributed to VIP signalling has at least two receptors and one competing endogenous ligand to account for.

Why is receptor selectivity between VPAC1 and VPAC2 difficult?

Because the two receptors recognise overlapping features of the same ligand. Pharmacophore mapping work from the early 2000s defined the requirements for each, and the 2022 structural work explains the overlap at the level of how the peptide binds.

Is VIP stable in solution?

Not especially. It is a 28-residue linear peptide with no stabilising modification, so it is exposed to proteolysis and to the usual chemical routes. The existence of a published programme to develop simplified, more stable analogues is itself evidence of the parent peptide’s fragility.

How does VIP relate to PACAP?

They are members of the same peptide family and share the VPAC receptors, though PACAP also has its own PAC1 receptor. Reagents and experiments involving one should account for the other, because the receptor overlap is substantial rather than incidental.

References

Igarashi H, et al. Elucidation of vasoactive intestinal peptide pharmacophore for VPAC(1) receptors in human, rat, and guinea pig. J Pharmacol Exp Ther. 2002. PMID: 11907155 https://pubmed.ncbi.nlm.nih.gov/11907155/
Igarashi H, et al. Elucidation of the vasoactive intestinal peptide pharmacophore for VPAC(2) receptors in human and rat and comparison to the pharmacophore for VPAC(1) receptors. J Pharmacol Exp Ther. 2002. PMID: 12388623 https://pubmed.ncbi.nlm.nih.gov/12388623/
Igarashi H, et al. Development of simplified vasoactive intestinal peptide analogs with receptor selectivity and stability for human vasoactive intestinal peptide/pituitary adenylate cyclase-activating polypeptide receptors. J Pharmacol Exp Ther. 2005. PMID: 15994369 https://pubmed.ncbi.nlm.nih.gov/15994369/
Piper SJ, et al. Understanding VPAC receptor family peptide binding and selectivity. Nat Commun. 2022. PMID: 36385145 https://pubmed.ncbi.nlm.nih.gov/36385145/